{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T13:50:09Z","timestamp":1780581009546,"version":"3.54.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2016,8,9]],"date-time":"2016-08-09T00:00:00Z","timestamp":1470700800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1208\/s12249-016-0604-1","type":"journal-article","created":{"date-parts":[[2016,8,9]],"date-time":"2016-08-09T12:51:26Z","timestamp":1470747086000},"page":"983-996","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Enhanced Solubility and Dissolution Rate of Lacidipine Nanosuspension: Formulation Via Antisolvent Sonoprecipitation Technique and Optimization Using Box\u2013Behnken Design"],"prefix":"10.1208","volume":"18","author":[{"given":"Mohamed A. A.","family":"Kassem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliaa N.","family":"ElMeshad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed R.","family":"Fares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,8,9]]},"reference":[{"key":"604_CR1","doi-asserted-by":"publisher","unstructured":"Patravale V, Dandekar P, Jain R. Nanoparticulate systems as drug carriers: the need. In: Nanoparticulate drug delivery. 1st ed: Woodhead Publishing; 2012. p. 1\u201328.","DOI":"10.1533\/9781908818195.1"},{"issue":"1\u20132","key":"604_CR2","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ijpharm.2010.07.044","volume":"399","author":"R Shegokar","year":"2010","unstructured":"Shegokar R, Muller RH. Nanocrystals: industrially feasible multifunctional formulation technology for poorly soluble actives. Int J Pharm. 2010;399(1\u20132):129\u201339.","journal-title":"Int J Pharm"},{"issue":"4","key":"604_CR3","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1208\/s12248-012-9383-0","volume":"14","author":"F Kesisoglou","year":"2012","unstructured":"Kesisoglou F, Mitra A. Crystalline nanosuspensions as potential toxicology and clinical oral formulations for BCS II\/IV compounds. AAPS J. 2012;14(4):677\u201387.","journal-title":"AAPS J"},{"issue":"2","key":"604_CR4","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.ejpb.2007.05.010","volume":"68","author":"M Vogt","year":"2008","unstructured":"Vogt M, Kunath K, Dressman JB. Dissolution enhancement of fenofibrate by micronization, cogrinding and spray-drying: comparison with commercial preparations. Eur J Pharm Biopharm. 2008;68(2):283\u20138.","journal-title":"Eur J Pharm Biopharm"},{"issue":"2","key":"604_CR5","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1208\/s12249-008-9057-5","volume":"9","author":"N Seedher","year":"2008","unstructured":"Seedher N, Kanojia M. Micellar solubilization of some poorly soluble antidiabetic drugs: a technical note. AAPS PharmSciTech. 2008;9(2):431\u20136.","journal-title":"AAPS PharmSciTech"},{"issue":"3","key":"604_CR6","doi-asserted-by":"publisher","first-page":"E33","DOI":"10.1208\/pt040333","volume":"4","author":"N Seedher","year":"2003","unstructured":"Seedher N, Bhatia S. Solubility enhancement of Cox-2 inhibitors using various solvent systems. AAPS PharmSciTech. 2003;4(3):E33.","journal-title":"AAPS PharmSciTech"},{"issue":"2","key":"604_CR7","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1208\/s12249-010-9404-1","volume":"11","author":"S Sinha","year":"2010","unstructured":"Sinha S, Ali M, Baboota S, Ahuja A, Kumar A, Ali J. Solid dispersion as an approach for bioavailability enhancement of poorly water-soluble drug ritonavir. AAPS PharmSciTech. 2010;11(2):518\u201327.","journal-title":"AAPS PharmSciTech"},{"issue":"1","key":"604_CR8","first-page":"E2","volume":"2","author":"Y Ran","year":"2001","unstructured":"Ran Y, Zhao L, Xu Q, Yalkowsky SH. Solubilization of cyclosporin A. AAPS PharmSciTech. 2001;2(1):E2.","journal-title":"AAPS PharmSciTech"},{"issue":"8","key":"604_CR9","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1080\/03639040500216220","volume":"31","author":"F Cao","year":"2005","unstructured":"Cao F, Guo J, Ping Q. The physicochemical characteristics of freeze-dried scutellarin-cyclodextrin tetracomponent complexes. Drug Dev Ind Pharm. 2005;31(8):747\u201356.","journal-title":"Drug Dev Ind Pharm"},{"issue":"3","key":"604_CR10","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.supflu.2006.12.002","volume":"42","author":"L Manna","year":"2007","unstructured":"Manna L, Banchero M, Sola D, Ferri A, Ronchetti S, Sicardi S. Impregnation of PVP microparticles with ketoprofen in the presence of supercritical CO2. J Supercrit Fluids. 2007;42(3):378\u201384.","journal-title":"J Supercrit Fluids"},{"issue":"3","key":"604_CR11","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.jconrel.2012.03.013","volume":"160","author":"L Gao","year":"2012","unstructured":"Gao L, Liu G, Ma J, Wang X, Zhou L, Li X. Drug nanocrystals: in vivo performances. J Control Release. 2012;160(3):418\u201330.","journal-title":"J Control Release"},{"issue":"1","key":"604_CR12","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.ijpharm.2013.01.019","volume":"453","author":"B Sinha","year":"2013","unstructured":"Sinha B, Muller RH, Moschwitzer JP. Bottom-up approaches for preparing drug nanocrystals: formulations and factors affecting particle size. Int J Pharm. 2013;453(1):126\u201341.","journal-title":"Int J Pharm"},{"issue":"1","key":"604_CR13","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ajps.2014.08.005","volume":"10","author":"VB Junyaprasert","year":"2015","unstructured":"Junyaprasert VB, Morakul B. Nanocrystals for enhancement of oral bioavailability of poorly water soluble drugs. Asian J Pharm Sci. 2015;10(1):13\u201323.","journal-title":"Asian J Pharm Sci"},{"issue":"3","key":"604_CR14","first-page":"295","volume":"3","author":"JU Junghanns","year":"2008","unstructured":"Junghanns JU, Muller RH. Nanocrystal technology, drug delivery and clinical applications. Int J Nanomedicine. 2008;3(3):295\u2013309.","journal-title":"Int J Nanomedicine"},{"issue":"3","key":"604_CR15","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1081\/DDC-52182","volume":"31","author":"P Langguth","year":"2005","unstructured":"Langguth P, Hanafy A, Frenzel D, Grenier P, Nhamias A, Ohlig T, et al. Nanosuspension formulations for low-soluble drugs: pharmacokinetic evaluation using spironolactone as model compound. Drug Dev Ind Pharm. 2005;31(3):319\u201329.","journal-title":"Drug Dev Ind Pharm"},{"issue":"2","key":"604_CR16","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1023\/A:1014276917363","volume":"19","author":"C Jacobs","year":"2002","unstructured":"Jacobs C, Muller RH. Production and characterization of a budesonide nanosuspension for pulmonary administration. Pharm Res. 2002;19(2):189\u201394.","journal-title":"Pharm Res"},{"issue":"3","key":"604_CR17","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.ejpb.2004.03.022","volume":"58","author":"J Moschwitzer","year":"2004","unstructured":"Moschwitzer J, Achleitner G, Pomper H, Muller RH. Development of an intravenously injectable chemically stable aqueous omeprazole formulation using nanosuspension technology. Eur J Pharm Biopharm. 2004;58(3):615\u20139.","journal-title":"Eur J Pharm Biopharm"},{"issue":"2","key":"604_CR18","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/S0928-0987(02)00251-8","volume":"18","author":"E Merisko-Liversidge","year":"2003","unstructured":"Merisko-Liversidge E, Liversidge GG, Cooper ER. Nanosizing: a formulation approach for poorly-water-soluble compounds. Eur J Pharm Sci. 2003;18(2):113\u201320.","journal-title":"Eur J Pharm Sci"},{"key":"604_CR19","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/0378-5173(95)00148-C","volume":"125","author":"GG Liversidge","year":"1995","unstructured":"Liversidge GG, Conzentino P. Drug particle size reduction for decreasing gastric irritancy and enhancing absorption of naproxen in rats. Int J Pharm. 1995;125:309\u201313.","journal-title":"Int J Pharm"},{"issue":"6","key":"604_CR20","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.addr.2010.12.007","volume":"63","author":"E Merisko-Liversidge","year":"2011","unstructured":"Merisko-Liversidge E, Liversidge GG. Nanosizing for oral and parenteral drug delivery: a perspective on formulating poorly-water soluble compounds using wet media milling technology. Adv Drug Deliv Rev. 2011;63(6):427\u201340.","journal-title":"Adv Drug Deliv Rev"},{"issue":"3","key":"604_CR21","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.ejpb.2011.07.005","volume":"79","author":"F Lai","year":"2011","unstructured":"Lai F, Pini E, Angioni G, Manca ML, Perricci J, Sinico C, et al. Nanocrystals as tool to improve piroxicam dissolution rate in novel orally disintegrating tablets. Eur J Pharm Biopharm. 2011;79(3):552\u20138.","journal-title":"Eur J Pharm Biopharm"},{"issue":"1","key":"604_CR22","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.ijpharm.2011.08.026","volume":"420","author":"K Mitri","year":"2011","unstructured":"Mitri K, Shegokar R, Gohla S, Anselmi C, Muller RH. Lutein nanocrystals as antioxidant formulation for oral and dermal delivery. Int J Pharm. 2011;420(1):141\u20136.","journal-title":"Int J Pharm"},{"issue":"1\u20132","key":"604_CR23","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.ijpharm.2011.05.075","volume":"415","author":"H Zhang","year":"2011","unstructured":"Zhang H, Hollis CP, Zhang Q, Li T. Preparation and antitumor study of camptothecin nanocrystals. Int J Pharm. 2011;415(1\u20132):293\u2013300.","journal-title":"Int J Pharm"},{"issue":"4","key":"604_CR24","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.ejps.2010.04.006","volume":"40","author":"D Xia","year":"2010","unstructured":"Xia D, Quan P, Piao H, Sun S, Yin Y, Cui F. Preparation of stable nitrendipine nanosuspensions using the precipitation-ultrasonication method for enhancement of dissolution and oral bioavailability. Eur J Pharm Sci. 2010;40(4):325\u201334.","journal-title":"Eur J Pharm Sci"},{"issue":"1","key":"604_CR25","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1208\/s12249-011-9750-7","volume":"13","author":"D Liu","year":"2012","unstructured":"Liu D, Xu H, Tian B, Yuan K, Pan H, Ma S, et al. Fabrication of carvedilol nanosuspensions through the anti-solvent precipitation-ultrasonication method for the improvement of dissolution rate and oral bioavailability. AAPS PharmSciTech. 2012;13(1):295\u2013304.","journal-title":"AAPS PharmSciTech"},{"key":"604_CR26","volume-title":"Design and analysis of experiments","author":"DC Montgomery","year":"2001","unstructured":"Montgomery DC. Design and analysis of experiments. 5th ed. New York: Wiley; 2001.","edition":"5"},{"issue":"2","key":"604_CR27","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.aca.2007.07.011","volume":"597","author":"SL Ferreira","year":"2007","unstructured":"Ferreira SL, Bruns RE, Ferreira HS, Matos GD, David JM, Brandao GC, et al. Box-Behnken design: an alternative for the optimization of analytical methods. Anal Chim Acta. 2007;597(2):179\u201386.","journal-title":"Anal Chim Acta"},{"issue":"4","key":"604_CR28","doi-asserted-by":"publisher","first-page":"E86","DOI":"10.1208\/pt0804086","volume":"8","author":"AB Solanki","year":"2007","unstructured":"Solanki AB, Parikh JR, Parikh RH. Formulation and optimization of piroxicam proniosomes by 3-factor, 3-level Box-Behnken design. AAPS PharmSciTech. 2007;8(4):E86.","journal-title":"AAPS PharmSciTech"},{"key":"604_CR29","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1201\/b14127-36","volume-title":"Hypertension: principles and practice","author":"DS Hanes","year":"2005","unstructured":"Hanes DS, Weir MR. Calcium antagonists. In: Battegay EJ, Lip GYH, Bakris GL, editors. Hypertension: principles and practice. USA: Taylor & Francis Group; 2005. p. 517\u201330."},{"issue":"1\u20132","key":"604_CR30","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.ijpharm.2014.06.048","volume":"472","author":"NA ElKasabgy","year":"2014","unstructured":"ElKasabgy NA, Elsayed I, Elshafeey AH. Design of lipotomes as a novel dual functioning nanocarrier for bioavailability enhancement of lacidipine: in-vitro and in-vivo characterization. Int J Pharm. 2014;472(1\u20132):369\u201379.","journal-title":"Int J Pharm"},{"issue":"1\u20132","key":"604_CR31","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.ijpharm.2010.03.008","volume":"391","author":"EB Basalious","year":"2010","unstructured":"Basalious EB, Shawky N, Badr-Eldin SM. SNEDDS containing bioenhancers for improvement of dissolution and oral absorption of lacidipine. I: development and optimization. Int J Pharm. 2010;391(1\u20132):203\u201311.","journal-title":"Int J Pharm"},{"issue":"1\u20132","key":"604_CR32","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.ijpharm.2009.12.050","volume":"388","author":"R Gannu","year":"2010","unstructured":"Gannu R, Palem CR, Yamsani VV, Yamsani SK, Yamsani MR. Enhanced bioavailability of lacidipine via microemulsion based transdermal gels: formulation optimization, ex vivo and in vivo characterization. Int J Pharm. 2010;388(1\u20132):231\u201341.","journal-title":"Int J Pharm"},{"key":"604_CR33","doi-asserted-by":"crossref","unstructured":"Zhao J, Luo L, Fu Q, Guo B, Li Y, Geng Y, et al. Improved oral bioavailability of lacidipine using nanosuspension technology: inferior in vitro dissolution and superior in vivo drug absorption verus lacipil(R). Curr Drug Deliv. 2015; in press.","DOI":"10.2174\/1567201812666150511094756"},{"issue":"3","key":"604_CR34","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s10847-016-0600-9","volume":"84","author":"T Darekar","year":"2016","unstructured":"Darekar T, Aithal KS, Shirodkar R, Kumar L, Attari Z, Lewis S. Characterization and in vivo evaluation of lacidipine inclusion complexes with \u03b2-cyclodextrin and its derivatives. J Incl Phenom Macrocycl Chem. 2016;84(3):225\u201335.","journal-title":"J Incl Phenom Macrocycl Chem"},{"key":"604_CR35","doi-asserted-by":"publisher","first-page":"19844","DOI":"10.1039\/C4RA16017G","volume":"5","author":"C Wu","year":"2015","unstructured":"Wu C, Kou L, Ma P, Gao L, Li B, Li R, et al. Interspecies prediction of oral pharmacokinetics of different lacidipine formulations from dogs to human: physiologically based pharmacokinetic modelling combined with biorelevant dissolution. RSC Adv. 2015;5:19844\u201352.","journal-title":"RSC Adv"},{"issue":"5","key":"604_CR36","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.3109\/10717544.2015.1132797","volume":"23","author":"SM Soliman","year":"2016","unstructured":"Soliman SM, Abdelmalak NS, El-Gazayerly ON, Abdelaziz N. Novel non-ionic surfactant proniosomes for transdermal delivery of lacidipine: optimization using 2(3) factorial design and in vivo evaluation in rabbits. Drug Deliv. 2016;23(5):1608\u201322.","journal-title":"Drug Deliv"},{"issue":"5","key":"604_CR37","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1080\/02652040802376429","volume":"26","author":"S Sultana","year":"2009","unstructured":"Sultana S, Bhavna, Iqbal Z, Panda BP, Talegaonkar S, Bhatnagar A, et al. Lacidipine encapsulated gastroretentive microspheres prepared by chemical denaturation for pylorospasm. J Microencapsul. 2009;26(5):385\u201393.","journal-title":"J Microencapsul"},{"issue":"2","key":"604_CR38","doi-asserted-by":"publisher","first-page":"90","DOI":"10.4103\/2230-973X.100048","volume":"2","author":"A Mukharya","year":"2012","unstructured":"Mukharya A, Chaudhary S, Mansuri N, Misra AK. Solid-state characterization of lacidipine\/PVP K(29\/32) solid dispersion primed by solvent co-evaporation. Int J Pharm Investig. 2012;2(2):90\u20136.","journal-title":"Int J Pharm Investig"},{"issue":"1\u20132","key":"604_CR39","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.ijpharm.2016.01.062","volume":"503","author":"M Sun","year":"2016","unstructured":"Sun M, Wu C, Fu Q, Di D, Kuang X, Wang C, et al. Solvent-shift strategy to identify suitable polymers to inhibit humidity-induced solid-state crystallization of lacidipine amorphous solid dispersions. Int J Pharm. 2016;503(1\u20132):238\u201346.","journal-title":"Int J Pharm"},{"issue":"8","key":"604_CR40","first-page":"1526","volume":"34","author":"R Shirodkar","year":"2015","unstructured":"Shirodkar R, Reddy N, Kumar N, Ramalingayya GV, Mutalik S, Lewis S. Subacute toxicity study of lacidipine nanoformulation. Lat Am J Pharm. 2015;34(8):1526\u201333.","journal-title":"Lat Am J Pharm"},{"issue":"2","key":"604_CR41","first-page":"50","volume":"2","author":"K Anuradha","year":"2014","unstructured":"Anuradha K, Kumar MS. Development of lacidipine loaded nanostructured lipid carriers (NLCs) for bioavailability enhancement. Int J Pharm Med Res. 2014;2(2):50\u20137.","journal-title":"Int J Pharm Med Res"},{"key":"604_CR42","first-page":"20","volume":"1","author":"SC Dinda","year":"2014","unstructured":"Dinda SC, Pand SK. Formulation and in-vitro\/in-vivo assessment of enhanced bioavailability of lacidipine using Nanopure technique. Albanian J Pharm Sci. 2014;1:20\u20135.","journal-title":"Albanian J Pharm Sci"},{"issue":"6","key":"604_CR43","doi-asserted-by":"publisher","first-page":"717","DOI":"10.3109\/10837450.2013.823994","volume":"19","author":"G Abdelbary","year":"2014","unstructured":"Abdelbary G, Makhlouf A. Adoption of polymeric micelles to enhance the oral bioavailability of dexibuprofen: formulation, in-vitro evaluation and in-vivo pharmacokinetic study in healthy human volunteers. Pharm Dev Technol. 2014;19(6):717\u201327.","journal-title":"Pharm Dev Technol"},{"issue":"1","key":"604_CR44","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1208\/s12249-014-0211-y","volume":"16","author":"J Hao","year":"2015","unstructured":"Hao J, Gao Y, Zhao J, Zhang J, Li Q, Zhao Z, et al. Preparation and optimization of resveratrol nanosuspensions by antisolvent precipitation using Box-Behnken design. AAPS PharmSciTech. 2015;16(1):118\u201328.","journal-title":"AAPS PharmSciTech"},{"issue":"4","key":"604_CR45","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1021\/js970361l","volume":"87","author":"S Tenjarla","year":"1998","unstructured":"Tenjarla S, Puranajoti P, Kasina R, Mandal T. Preparation, characterization, and evaluation of miconazole-cyclodextrin complexes for improved oral and topical delivery. J Pharm Sci. 1998;87(4):425\u20139.","journal-title":"J Pharm Sci"},{"issue":"3","key":"604_CR46","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/j.ejpb.2007.09.007","volume":"68","author":"Y Gonnissen","year":"2008","unstructured":"Gonnissen Y, Goncalves SI, De Geest BG, Remon JP, Vervaet C. Process design applied to optimise a directly compressible powder produced via a continuous manufacturing process. Eur J Pharm Biopharm. 2008;68(3):760\u201370.","journal-title":"Eur J Pharm Biopharm"},{"issue":"2","key":"604_CR47","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.ijpharm.2010.02.013","volume":"390","author":"J Deng","year":"2010","unstructured":"Deng J, Huang L, Liu F. Understanding the structure and stability of paclitaxel nanocrystals. Int J Pharm. 2010;390(2):242\u20139.","journal-title":"Int J Pharm"},{"key":"604_CR48","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jcis.2013.05.058","volume":"407","author":"N Wang","year":"2013","unstructured":"Wang N, Hsu C, Zhu L, Tseng S, Hsu JP. Influence of metal oxide nanoparticles concentration on their zeta potential. J Colloid Interface Sci. 2013;407:22\u20138.","journal-title":"J Colloid Interface Sci"},{"issue":"8","key":"604_CR49","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1002\/jps.20644","volume":"95","author":"B Shah","year":"2006","unstructured":"Shah B, Kakumanu VK, Bansal AK. Analytical techniques for quantification of amorphous\/crystalline phases in pharmaceutical solids. J Pharm Sci. 2006;95(8):1641\u201365.","journal-title":"J Pharm Sci"},{"issue":"1\u20132","key":"604_CR50","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.ijpharm.2008.11.029","volume":"370","author":"R Mauludin","year":"2009","unstructured":"Mauludin R, Muller RH, Keck CM. Development of an oral rutin nanocrystal formulation. Int J Pharm. 2009;370(1\u20132):202\u20139.","journal-title":"Int J Pharm"}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-016-0604-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1208\/s12249-016-0604-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-016-0604-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-016-0604-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,12]],"date-time":"2019-09-12T05:57:53Z","timestamp":1568267873000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1208\/s12249-016-0604-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,9]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["604"],"URL":"https:\/\/doi.org\/10.1208\/s12249-016-0604-1","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,9]]}}}